Carlsmed
CARL
48 hedge funds and large institutions have $62.4M invested in Carlsmed in 2025 Q3 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
17.53% more ownership
Funds ownership: 0% → 17.53% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$17.1M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$14.9M |
| 3 |
BlackRock
New York
|
+$5.27M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$4.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.11M |
Top Sellers
CARL Hedge Fund Activity: Q3 2025 in Review
48 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Carlsmed (CARL) for Q3 2025, worth a combined $62.4M.
Buyers outnumbered sellers: 48 funds opened new CARL positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $17.1M.
- 48 institutional investors held Carlsmed (CARL) as of Q3 2025, up from 0 in Q2 2025.
- Funds reported $62.4M of Carlsmed stock for Q3 2025.
- 48 funds opened new Carlsmed positions in Q3 2025 and 0 closed out, a net change of +48 holders.
- The largest Carlsmed buyer in Q3 2025 was OrbiMed, an estimated $17.1M added.
Based on aggregated 13F filings for Q3 2025.